The management of type 2 diabetes has improved with the evolution of new pharmaceuticals, insulin delivery devices and surgical procedures. In spite of these improvements, there continues to be a number of unmet needs that leave patients at risk for the progression of, or co-morbid conditions associated with, type 2 diabetes.

New non-surgical therapeutics are emerging with the potential to fill the gap between pharmaceutical regimens and surgery. These innovative devices will initially benefit patients who have not been able to manage their type 2 diabetes with lifestyle adjustments or medications and for whom the risks of surgery are unacceptable. Ultimately, these devices may also serve the needs of patients earlier in the stage of their disease, or later to complement pharmaceutical agents.

There is a clear need for treatment alternatives for patients who are not responsive to medical therapy and do not see surgery as an option. GI Dynamics’ EndoBarrier® Therapy is a revolutionary approach to help patients take better control of their health.